Literature DB >> 29134617

Vascular calcification is not related to serum fetuin-A and osteopontin levels in hemodialysis patients.

O Ulutas1, M C Taskapan2, A Dogan3, T Baysal4, H Taskapan5.   

Abstract

INTRODUCTION: Vascular calcification (VC) in hemodialysis (HD) patients is a sign of severe cardiovascular disease and can predict cardiovascular outcomes. Fetuin-A and osteopontin (OPN) inhibit VC. Serum fetuin-A levels are lower in patients with end-stage kidney disease (ESKD) and in those who are on chronic HD therapy. However, there are limited data concerning OPN in patients who are on dialysis. The aim of our study was to determine VC in HD patients, the relationship between VC and 25-OH-vitamin D, fetuin-A, and OPN levels, and independent predictors of VC.
MATERIALS AND METHODS: Ninety-three patients with ESKD on HD therapy were recruited. Among these patients, 44 were male and 49 were female. The patient group was compared with a group of 20 healthy controls of similar age and sex. A plain radiograph of the hand was taken using a mammography machine for the evaluation of VC. Serum fetuin-A, OPN, and 25-OH-vitamin D levels of both patients and controls were measured.
RESULTS: VC was detected in 45 (48.4%) HD patients. When patients were compared with healthy controls, fetuin-A levels (p < 0.029) were significantly lower in patients, whereas OPN (p < 0.000) and VC (p < 0.002) were significantly higher in the patient group. Age [odds ratio (OR) 1.036], the presence of diabetes mellitus (DM) (OR 17.527), and high parathyroid hormone (PTH) levels (OR 1.002) were independent predictors of VC in a logistic regression model including the following factors: age, the presence of DM, HD duration, and serum albumin, phosphate, PTH, 25-OH-vitamin D, fetuin-A, OPN, and calcium levels. No significant correlation was found between patients with VC and patients without VC in terms of fetuin-A, OPN, and 25-OH-vitamin D levels.
CONCLUSIONS: VC is a frequent sign in patients undergoing HD and is not related to serum fetuin-A and osteopontin levels. Age, the presence of DM, and high PTH levels were independent predictors of VC in patients undergoing HD. Further studies are warranted to understand the mechanism underlying and the factors contributing to VC.

Entities:  

Keywords:  Fetuin-A; Hemodialysis; Osteopontin; Vascular calcinosis

Mesh:

Substances:

Year:  2017        PMID: 29134617     DOI: 10.1007/s11255-017-1740-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  25 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

4.  Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin.

Authors:  T Wada; M D McKee; S Steitz; C M Giachelli
Journal:  Circ Res       Date:  1999-02-05       Impact factor: 17.367

5.  Progression of coronary artery calcification in predialysis patients.

Authors:  Domenico Russo; Salvatore Corrao; Ida Miranda; Carolina Ruocco; Simona Manzi; Rosanna Elefante; Diego Brancaccio; Mario Cozzolino; Maria L Biondi; Vittorio E Andreucci
Journal:  Am J Nephrol       Date:  2007-02-20       Impact factor: 3.754

6.  Fetuin-A protects against atherosclerotic calcification in CKD.

Authors:  Ralf Westenfeld; Cora Schäfer; Thilo Krüger; Christian Haarmann; Leon J Schurgers; Chris Reutelingsperger; Ognen Ivanovski; Tilman Drueke; Ziad A Massy; Markus Ketteler; Jürgen Floege; Willi Jahnen-Dechent
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

7.  Bone morphogenetic protein expression in human atherosclerotic lesions.

Authors:  K Boström; K E Watson; S Horn; C Wortham; I M Herman; L L Demer
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis.

Authors:  Sijie Zheng; Lisa de Las Fuentes; Andrew Bierhals; Rachel Ash-Bernal; Karen Spence; Eduardo Slatopolsky; Victor G Davila-Roman; James Delmez
Journal:  Am J Cardiol       Date:  2008-10-30       Impact factor: 2.778

9.  Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis.

Authors:  Hae Hyuk Jung; Sang-Wook Kim; Heon Han
Journal:  Nephrol Dial Transplant       Date:  2006-03-22       Impact factor: 5.992

10.  Osteopontin, a new prognostic biomarker in patients with chronic heart failure.

Authors:  Mark Rosenberg; Christian Zugck; Manfred Nelles; Claus Juenger; Derk Frank; Andrew Remppis; Evangelos Giannitsis; Hugo A Katus; Norbert Frey
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

View more
  5 in total

1.  Kidney Diseases: The Age of Molecular Markers.

Authors:  Glaucia Luciano da Veiga; Beatriz da Costa Aguiar Alves; Matheus Moreira Perez; Joyce Regina Raimundo; Jéssica Freitas de Araújo Encinas; Neif Murad; Fernando Luiz Affonso Fonseca
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).

Authors:  Julie Contenti; Matthieu Durand; Sandor Vido; Serge Declemy; Juliette Raffort; Joseph Carboni; Sophie Bonnet; Christophe Koelsch; Réda Hassen-Khodja; Philippe Gual; Nathalie M Mazure; Nirvana Sadaghianloo
Journal:  J Nephrol       Date:  2021-09-01       Impact factor: 3.902

4.  Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients.

Authors:  Jessica Fitzpatrick; Esther D Kim; Stephen M Sozio; Bernard G Jaar; Michelle M Estrella; Jose M Monroy-Trujillo; Rulan S Parekh
Journal:  Kidney Int Rep       Date:  2020-08-06

Review 5.  Vascular Calcification: Key Roles of Phosphate and Pyrophosphate.

Authors:  Ricardo Villa-Bellosta
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.